-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NTC-801 in Arrhythmias
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NTC-801 in Arrhythmias report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NTC-801 in Arrhythmias Drug Details: NTC-801 (BMS-914392) is under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NTC-011 in Otitis Externa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NTC-011 in Otitis Externa report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NTC-011 in Otitis ExternaDrug Details:NTC-011 is under development for the treatment of otitis...
-
Product Insights
Bacterial Conjunctivitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Bacterial Conjunctivitis - Drugs In Development, 2023’, provides an overview of the Bacterial Conjunctivitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bacterial Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Blepharitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Blepharitis - Drugs In Development, 2023’, provides an overview of the Blepharitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Blepharitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Otitis Media – Drugs In Development, 2023
Global Markets Direct’s, ‘Otitis Media - Drugs In Development, 2023’, provides an overview of the Otitis Media pipeline landscape. The report provides comprehensive information on the therapeutics under development for Otitis Media, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Conjunctivitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Conjunctivitis - Drugs In Development, 2023’, provides an overview of the Conjunctivitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – B-4T2001 in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - B-4T2001 in Metastatic Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. B-4T2001 in Metastatic Pancreatic Cancer Drug Details: B4T2-001 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – B-4T2001 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - B-4T2001 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. B-4T2001 in Solid Tumor Drug Details: B4T2-001 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NT-501 in Glaucoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NT-501 in Glaucoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NT-501 in Glaucoma Drug Details: NT-501 is under development for the treatment of...